Learn how you can manage and alleviate your current side effects while actively working to prevent a relapse or secondary cancer using evidence-based, non-toxic therapies.
Click the orange button to the right to learn more.
A diagnosis of prostate cancer doesn’t really give you actionable information these days. It is the stage at diagnosis and prognosis that results from your diagnosis of prostate cancer that really matters to you.
On the one hand you could live with slow-growing prostate cancer in your prostate for the rest of your life and die peacefully in your sleep in your nineties. Conversely, you could be diagnosed with prostate cancer and it could grow, spread to other parts of your body and you could die a young man.
So what is a newly diagnosed man with prostate cancer supposed to do? The challenge you face is that active treatment of prostate cancer will cause side effects- potentially serious side effects.
If you have prostate cancer that is low risk meaning that you have little risk of developing real health problems from your prostate cancer, you might want to utilize evidence-based but non-conventional therapies shown to reduce your risks further.
I am both a long-term cancer survivor and cancer coach. I work with cancer patients and survivors to provide the most effective of both conventional (FDA approved) and evidence-based but non-conventional therapies.
Click the links below to learn more about low-risk Prostate Cancer-
For more information on prostate cancer supplementation, lifestyle therapies and nutrition, please scroll down the page, post a question or a comment and I will reply to you ASAP.
“One of the most important problems in urological practice is how to differentiate clinically significant and non significant prostate cancer (Pca) i.e. how to avoid over treatment of tumors with low malignant potential in one hand, and inappropriate less aggressive treatment of significant tumors, on the other hand…
Transrectal ultrasound—guided prostate biopsy id the golden standard, but there are few dilemmas concerning prostate biopsy: the number of biopsy cores, inter and intra-observer variations in the grading, the significance of PIN, multifocal character of PCa etc.”
“The Prostate Health Index (phi), a blood test that combines 3 PSA measurements into a single score, improves detection of clinically significant prostate cancer (PCa) and could help decrease the number of unnecessary prostate biopsies, researchers reported…
The researchers used the Epstein definition of clinically significant PCa (Gleason score 7 or higher, 3 or more positive cores, and more than 50% involvement of any core)…
The test measures total, free, and [-2]proPSA (p2PSA), the latter being an isoform of free PSA identified as the most PCa-specific form found in tumor extracts…
“Phi is a simple blood test that we recommend for use as part of a multivariable approach to reduce unnecessary biopsies and over diagnosis,” the authors concluded…
Dr. Loeb’s group acknowledged some study limitations, including the use of biopsy criteria to define clinical significance. “Although biopsy criteria are frequently used, these end points are not perfect and other factors such as life expectancy also have a key role in defining over diagnosis,” they wrote…”
“…The result provided by the Oncotype DX prostate test is called your Genomic Prostate Score (GPS). Your GPS provides important information about how aggressive your cancer is based on the biology of your individual tumor. Used along with other test results, your GPS can help to personalize your treatment plan and give you and your doctor greater confidence in choosing your course of care….”
“What are the recent trends and ongoing variation in the use of active surveillance for patients diagnosed with low-risk PCa…
In a cohort study of more than 20 000 men treated at nearly 350 urology practices across the US, with data drawn directly from electronic health record systems, rates of active surveillance increased sharply from 26.5% in 2014 to 59.6% in 2021…
Participants This retrospective analysis of a prospective cohort study included men with low-risk prostate cancer,
newly diagnosed between January 1, 2014, and June 1, 2021..
Results A total of 20 809 patients in AQUA were diagnosed with low-risk PCa and had known primary treatment. The median age was 65 (IQR, 59-70) years; 31 (0.1%) were American Indian or Alaska Native; 148 (0.7%) were Asian or Pacific Islander; 1855 (8.9%) were Black; 8351 (40.1%) were White; 169 (0.8%) were of other race or ethnicity; and 10 255 (49.3%) were missing information on race or ethnicity.
Rates of AS increased sharply and consistently from 26.5% in 2014 to 59.6% in 2021. However, use of AS varied from 4.0% to 78.0% at the urology practice level and from 0% to 100% at the practitioner level. On multivariable analysis, year of diagnosis was the variable most strongly associated with AS; age, race, and PSA value at diagnosis were all also associated with odds of surveillance.
Conclusions and Relevance This cohort study of AS rates in the AQUA Registry found that national, community-based rates of AS have increased but remain suboptimal, and wide variation persists across practices and practitioners. Continued progress on this critical quality indicator is essential to minimize overtreatment of low-risk PCa and by extension to improve the benefit-to-harm ratio of national prostate cancer early detection efforts…